Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

OBJECTIVE: The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially plati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeh Chen, King, Madeleine T, O'Connell, Rachel L, Lanceley, Anne, Joly, Florence, Hilpert, Felix, Davis, Alison, Roncolato, Felicia T, Okamoto, Aikou, Bryce, Jane, Donnellan, Paul, Oza, Amit M, Avall-Lundqvist, Elisabeth, Berek, Jonathan S, Ledermann, Jonathan A, Berton, Dominique, Sehouli, Jalid, Feeney, Amanda, Kaminsky, Marie-Christine, Diamante, Katrina, Stockler, Martin R, Friedlander, Michael L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185817/
https://www.ncbi.nlm.nih.gov/pubmed/35086926
http://dx.doi.org/10.1136/ijgc-2021-003142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185817/
https://www.ncbi.nlm.nih.gov/pubmed/35086926
http://dx.doi.org/10.1136/ijgc-2021-003142

Ejemplares similares